Immune checkpoint inhibitors - Anti-PD-1 (same as Pembro)
Used in the treatment of Oesophageal cancer after resection in patients with residual disease based on:
- CheckMate 577 trial
- 794 patients who had received neoadjuvant CRT for esophageal or EGJ cancer (70 percent AC)
- Nivolumab (240 mg) or placebo every 2 weeks for 16 weeks followed by nivolumab 480 mg or placebo every 4 weeks
- Primary end point
- median disease-free survival- (22.4 versus 11 months) across all groups